Abdul-Jawad, S;
Baù, L;
Alaguthurai, T;
Del Molino Del Barrio, I;
Laing, AG;
Hayday, TS;
Monin, L;
... Irshad, S; + view all
(2021)
Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients.
Cancer Cell
10.1016/j.ccell.2021.01.001.
(In press).
Preview |
Text
Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients.pdf - Published Version Download (3MB) | Preview |
Abstract
Given the immune system’s importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients’ immunophenotypes resemble those of nonvirus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.
| Type: | Article |
|---|---|
| Title: | Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ccell.2021.01.001 |
| Publisher version: | https://doi.org/10.1016/j.ccell.2021.01.001 |
| Language: | English |
| Additional information: | This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | COVID-19, SARS-CoV-2, antibodies, cancer, hemato-oncological, immune, seroconversion, vaccine, virus shedding |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10120638 |
Archive Staff Only
 |
View Item |
